GDF-15 and side effects study for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks at a substance called GDF-15 in the blood and how it relates to side effects, especially weight loss, in people starting a breast cancer drug called T-DXd.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced breast cancer (spread or cannot be removed by surgery) that is HER2-positive or HER2-low.
- You are about to start treatment with the drug T-DXd.
- Your doctor expects you to live at least 4 more months.
- You are not currently on a strict diet for weight loss or receiving tube feeding or IV nutrition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This trial tests a new drug called Dato-DXd for people with a specific type of breast cancer that is hormone receptor-positive and HER2-negative (IHC 0). It's for those whose cancer has stopped responding to hormone therapy and who haven't had chemotherapy for cancer that has spread.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This study looks at people with advanced breast cancer who will receive a drug called T-DXd. Researchers want to understand the side effects of this treatment by analyzing blood samples.
This trial is studying a drug called T-DXd (trastuzumab deruxtecan) for Chinese women with advanced breast cancer that has a certain protein (HER2) either in high or low amounts. It aims to see how well the drug works in real-world settings.
This trial studies how the drug T-DXd (trastuzumab-deruxtecan) works in people with advanced or metastatic breast cancer. It compares drug levels in the body based on body mass index (BMI) to see if dose adjustments are needed.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.